相关实验视频
Updated: Jun 26, 2025

06:02
Detection of Neuritic Plaques in Alzheimer's Disease Mouse Model
Published on: July 26, 2011
36.7K
在阿尔茨海默氏病中,斑块和微质糖化形成的明显模式
Caitlyn Fastenau1,2, Madison Bunce1, Mallory Keating2
1Department of Pharmacology, University of Texas Health Science Center San Antonio, San Antonio, Texas, USA.
Brain pathology (Zurich, Switzerland)
|May 9, 2024
概括
这就是阿尔茨海默病的原因.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生物化学
- 病理学 病理学 病理学
背景情况:
- 糖化,一个常见的大脑修饰,在阿尔茨海默病 (AD) 中发生变化,特别是酸 (SA) 水平.
- 之前的研究缺乏空间分辨率,无法精确地确定AD脑组织中SA修饰的糖.
- 在神经退行症中,N连接和O连接的 Sialated Glycans 仍然没有得到充分的研究.
研究的目的:
- 在死后AD脑组织中对N和O结合甘氨酸的化景观进行空间特征.
- 调查化模式与阿尔茨海默病病理学之间的关系,包括粉样β (Aβ) 斑块和化.
- 通过了解化在AD中的作用来确定潜在的治疗点.
主要方法:
- 利用了新的组织学技术和定量数字病理学.
- 分析了尸检确认的AD脑组织,来自10个病例,分布在三个区域:额叶皮质,海马体和小脑.
- 评估了与Aβ斑块和tau病理学相关的N-和O结合的化甘氨酸的位置和分布.
主要成果:
- 与O-化相比,在Aβ斑块微环境中发现了显著更高的N-化.
- 与斑块相关的微细胞表现出最强烈的N-化.
- 在核心型和扩散型Aβ斑块形态之间观察到明显的N-和O-化差异.
- 酸化病理略微增加了N-化,但没有影响O-化.
结论:
- 微质化与AD蛋白聚合物,特别是Aβ斑块有关.
- 化模式根据斑块形态和病理不同.
- 这些发现突出了针对阿尔茨海默病中微质化治疗的潜在治疗策略.
相关概念视频
Alzheimer's Disease: Overview
467
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
467
Amyloid Fibrils
9.5K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.5K
Alzheimer's Disease: Treatment
181
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
181

